
    
      The objective is to carry out a randomized blinded placebo-controlled trial of inhaled
      Albuterol as an early therapy for patients with decompensated Congestive Heart Failure.
      Compared to placebo, inhaled Albuterol will improve oxygenation and decrease the need for
      non-invasive ventilation in patients with Cardiogenic Pulmonary Edema.
    
  